Plasma phospholipid n-3 and n-6 polyunsaturated fatty acids in relation to cardiometabolic markers and gestational diabetes: A longitudinal study within the prospective NICHD Fetal Growth Studies.
<h4>Background</h4>Despite dietary recommendations of polyunsaturated fatty acids (PUFAs) for cardiometabolic health, n-3 and n-6 PUFAs and their interplay in relation to diabetes risk remain debated. Importantly, data among pregnant women are scarce. We investigated individual plasma ph...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2019-09-01
|
| Series: | PLoS Medicine |
| Online Access: | https://doi.org/10.1371/journal.pmed.1002910 |
| _version_ | 1818743890872631296 |
|---|---|
| author | Yeyi Zhu Mengying Li Mohammad L Rahman Stefanie N Hinkle Jing Wu Natalie L Weir Yuan Lin Huixia Yang Michael Y Tsai Assiamira Ferrara Cuilin Zhang |
| author_facet | Yeyi Zhu Mengying Li Mohammad L Rahman Stefanie N Hinkle Jing Wu Natalie L Weir Yuan Lin Huixia Yang Michael Y Tsai Assiamira Ferrara Cuilin Zhang |
| author_sort | Yeyi Zhu |
| collection | DOAJ |
| description | <h4>Background</h4>Despite dietary recommendations of polyunsaturated fatty acids (PUFAs) for cardiometabolic health, n-3 and n-6 PUFAs and their interplay in relation to diabetes risk remain debated. Importantly, data among pregnant women are scarce. We investigated individual plasma phospholipid n-3 and n-6 PUFAs in early to midpregnancy in relation to subsequent risk of gestational diabetes mellitus (GDM).<h4>Methods and findings</h4>Within the National Institute of Child Health and Human Development (NICHD) Fetal Growth Studies-Singleton Cohort (n = 2,802), individual plasma phospholipid n-3 and n-6 PUFAs levels were measured at gestational weeks (GWs) 10-14, 15-26, 23-31, and 33-39 among 107 GDM cases (ascertained on average at GW 27) and 214 non-GDM controls. Conditional logistic regression was used, adjusting for major risk factors for GDM. After adjusting for covariates, individual n-3 eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA), and docosahexaenoic acid (DHA) were inversely correlated with insulin-resistance markers, whereas individual n-6 dihomo-gamma-linolenic acid (DGLA) was positively correlated with insulin-resistance markers. At GW 15-26, a standard deviation (SD) increase in total n-3 PUFAs and individual n-3 DPA was associated with a 36% (adjusted odds ratio 0.64; 95% CI 0.42-0.96; P = 0.042) and 33% (0.67; 95% CI 0.45-0.99; P = 0.047) lower risk of GDM, respectively; however, the significance did not persist after post hoc false-discovery rate (FDR) correction (FDR-corrected P values > 0.05). Associations between total n-6 PUFAs and GDM were null, whereas associations with individual n-6 PUFAs were differential. Per SD increase, gamma-linolenic acid (GLA) at GWs 10-14 and DGLA at GWs 10-14 and 15-26 were significantly associated with a 1.40- to 1.95-fold higher risk of GDM, whereas docosatetraenoic acid (DTA) at GW 15-26 was associated with a 45% (0.55; 95% CI 0.37-0.83) lower risk of GDM (all FDR-corrected P values < 0.05). Null associations were observed for linoleic acid (LA) in either gestational window in relation to risk of GDM. Women with high (≥median) n-3 PUFAs and low (<median) n-6 PUFAs levels had a 64% (95% CI 0.14-0.95; P value = 0.039) lower risk of GDM versus women with low n-3 and high n-6 PUFAs. Limitations include the inability to distinguish between exogenous and endogenous influences on circulating PUFA levels and the lack of causality inherent in observational studies.<h4>Conclusions</h4>Our findings may suggest a potential role of primarily endogenously metabolized plasma phospholipid n-6 PUFAs including GLA, DGLA, and DTA in early to midpregnancy in the development of GDM. Null findings on primarily diet-derived n-3 EPA and DHA and n-6 LA do not provide strong evidence to suggest a beneficial role in prevention of GDM, although not excluding the potential benefit of EPA and DHA on glucose-insulin homeostasis given the inverse associations with insulin-resistance markers. Our findings highlight the importance of assessing individual circulating PUFAs to investigate their distinct pathophysiologic roles in glucose homeostasis in pregnancy. |
| first_indexed | 2024-12-18T02:35:36Z |
| format | Article |
| id | doaj.art-73a405ba6c054de7a77a06a147c612ff |
| institution | Directory Open Access Journal |
| issn | 1549-1277 1549-1676 |
| language | English |
| last_indexed | 2024-12-18T02:35:36Z |
| publishDate | 2019-09-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS Medicine |
| spelling | doaj.art-73a405ba6c054de7a77a06a147c612ff2022-12-21T21:23:48ZengPublic Library of Science (PLoS)PLoS Medicine1549-12771549-16762019-09-01169e100291010.1371/journal.pmed.1002910Plasma phospholipid n-3 and n-6 polyunsaturated fatty acids in relation to cardiometabolic markers and gestational diabetes: A longitudinal study within the prospective NICHD Fetal Growth Studies.Yeyi ZhuMengying LiMohammad L RahmanStefanie N HinkleJing WuNatalie L WeirYuan LinHuixia YangMichael Y TsaiAssiamira FerraraCuilin Zhang<h4>Background</h4>Despite dietary recommendations of polyunsaturated fatty acids (PUFAs) for cardiometabolic health, n-3 and n-6 PUFAs and their interplay in relation to diabetes risk remain debated. Importantly, data among pregnant women are scarce. We investigated individual plasma phospholipid n-3 and n-6 PUFAs in early to midpregnancy in relation to subsequent risk of gestational diabetes mellitus (GDM).<h4>Methods and findings</h4>Within the National Institute of Child Health and Human Development (NICHD) Fetal Growth Studies-Singleton Cohort (n = 2,802), individual plasma phospholipid n-3 and n-6 PUFAs levels were measured at gestational weeks (GWs) 10-14, 15-26, 23-31, and 33-39 among 107 GDM cases (ascertained on average at GW 27) and 214 non-GDM controls. Conditional logistic regression was used, adjusting for major risk factors for GDM. After adjusting for covariates, individual n-3 eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA), and docosahexaenoic acid (DHA) were inversely correlated with insulin-resistance markers, whereas individual n-6 dihomo-gamma-linolenic acid (DGLA) was positively correlated with insulin-resistance markers. At GW 15-26, a standard deviation (SD) increase in total n-3 PUFAs and individual n-3 DPA was associated with a 36% (adjusted odds ratio 0.64; 95% CI 0.42-0.96; P = 0.042) and 33% (0.67; 95% CI 0.45-0.99; P = 0.047) lower risk of GDM, respectively; however, the significance did not persist after post hoc false-discovery rate (FDR) correction (FDR-corrected P values > 0.05). Associations between total n-6 PUFAs and GDM were null, whereas associations with individual n-6 PUFAs were differential. Per SD increase, gamma-linolenic acid (GLA) at GWs 10-14 and DGLA at GWs 10-14 and 15-26 were significantly associated with a 1.40- to 1.95-fold higher risk of GDM, whereas docosatetraenoic acid (DTA) at GW 15-26 was associated with a 45% (0.55; 95% CI 0.37-0.83) lower risk of GDM (all FDR-corrected P values < 0.05). Null associations were observed for linoleic acid (LA) in either gestational window in relation to risk of GDM. Women with high (≥median) n-3 PUFAs and low (<median) n-6 PUFAs levels had a 64% (95% CI 0.14-0.95; P value = 0.039) lower risk of GDM versus women with low n-3 and high n-6 PUFAs. Limitations include the inability to distinguish between exogenous and endogenous influences on circulating PUFA levels and the lack of causality inherent in observational studies.<h4>Conclusions</h4>Our findings may suggest a potential role of primarily endogenously metabolized plasma phospholipid n-6 PUFAs including GLA, DGLA, and DTA in early to midpregnancy in the development of GDM. Null findings on primarily diet-derived n-3 EPA and DHA and n-6 LA do not provide strong evidence to suggest a beneficial role in prevention of GDM, although not excluding the potential benefit of EPA and DHA on glucose-insulin homeostasis given the inverse associations with insulin-resistance markers. Our findings highlight the importance of assessing individual circulating PUFAs to investigate their distinct pathophysiologic roles in glucose homeostasis in pregnancy.https://doi.org/10.1371/journal.pmed.1002910 |
| spellingShingle | Yeyi Zhu Mengying Li Mohammad L Rahman Stefanie N Hinkle Jing Wu Natalie L Weir Yuan Lin Huixia Yang Michael Y Tsai Assiamira Ferrara Cuilin Zhang Plasma phospholipid n-3 and n-6 polyunsaturated fatty acids in relation to cardiometabolic markers and gestational diabetes: A longitudinal study within the prospective NICHD Fetal Growth Studies. PLoS Medicine |
| title | Plasma phospholipid n-3 and n-6 polyunsaturated fatty acids in relation to cardiometabolic markers and gestational diabetes: A longitudinal study within the prospective NICHD Fetal Growth Studies. |
| title_full | Plasma phospholipid n-3 and n-6 polyunsaturated fatty acids in relation to cardiometabolic markers and gestational diabetes: A longitudinal study within the prospective NICHD Fetal Growth Studies. |
| title_fullStr | Plasma phospholipid n-3 and n-6 polyunsaturated fatty acids in relation to cardiometabolic markers and gestational diabetes: A longitudinal study within the prospective NICHD Fetal Growth Studies. |
| title_full_unstemmed | Plasma phospholipid n-3 and n-6 polyunsaturated fatty acids in relation to cardiometabolic markers and gestational diabetes: A longitudinal study within the prospective NICHD Fetal Growth Studies. |
| title_short | Plasma phospholipid n-3 and n-6 polyunsaturated fatty acids in relation to cardiometabolic markers and gestational diabetes: A longitudinal study within the prospective NICHD Fetal Growth Studies. |
| title_sort | plasma phospholipid n 3 and n 6 polyunsaturated fatty acids in relation to cardiometabolic markers and gestational diabetes a longitudinal study within the prospective nichd fetal growth studies |
| url | https://doi.org/10.1371/journal.pmed.1002910 |
| work_keys_str_mv | AT yeyizhu plasmaphospholipidn3andn6polyunsaturatedfattyacidsinrelationtocardiometabolicmarkersandgestationaldiabetesalongitudinalstudywithintheprospectivenichdfetalgrowthstudies AT mengyingli plasmaphospholipidn3andn6polyunsaturatedfattyacidsinrelationtocardiometabolicmarkersandgestationaldiabetesalongitudinalstudywithintheprospectivenichdfetalgrowthstudies AT mohammadlrahman plasmaphospholipidn3andn6polyunsaturatedfattyacidsinrelationtocardiometabolicmarkersandgestationaldiabetesalongitudinalstudywithintheprospectivenichdfetalgrowthstudies AT stefanienhinkle plasmaphospholipidn3andn6polyunsaturatedfattyacidsinrelationtocardiometabolicmarkersandgestationaldiabetesalongitudinalstudywithintheprospectivenichdfetalgrowthstudies AT jingwu plasmaphospholipidn3andn6polyunsaturatedfattyacidsinrelationtocardiometabolicmarkersandgestationaldiabetesalongitudinalstudywithintheprospectivenichdfetalgrowthstudies AT natalielweir plasmaphospholipidn3andn6polyunsaturatedfattyacidsinrelationtocardiometabolicmarkersandgestationaldiabetesalongitudinalstudywithintheprospectivenichdfetalgrowthstudies AT yuanlin plasmaphospholipidn3andn6polyunsaturatedfattyacidsinrelationtocardiometabolicmarkersandgestationaldiabetesalongitudinalstudywithintheprospectivenichdfetalgrowthstudies AT huixiayang plasmaphospholipidn3andn6polyunsaturatedfattyacidsinrelationtocardiometabolicmarkersandgestationaldiabetesalongitudinalstudywithintheprospectivenichdfetalgrowthstudies AT michaelytsai plasmaphospholipidn3andn6polyunsaturatedfattyacidsinrelationtocardiometabolicmarkersandgestationaldiabetesalongitudinalstudywithintheprospectivenichdfetalgrowthstudies AT assiamiraferrara plasmaphospholipidn3andn6polyunsaturatedfattyacidsinrelationtocardiometabolicmarkersandgestationaldiabetesalongitudinalstudywithintheprospectivenichdfetalgrowthstudies AT cuilinzhang plasmaphospholipidn3andn6polyunsaturatedfattyacidsinrelationtocardiometabolicmarkersandgestationaldiabetesalongitudinalstudywithintheprospectivenichdfetalgrowthstudies |